ClinicalTrials.Veeva

Menu

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

V

Vistakon Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis

Treatments

Drug: R89674 (generic name not yet established)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00223951
05-003-10

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers

Sex

All

Ages

3+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

healthy normal volunteers age >=3 years with normal ocular health and a best-corrected logMAR score of 0.3 or better

Exclusion criteria

intraocular surgery and/or ocular surgical intervention within last 3 months, refractive surgery within last 6 months, active ocular disorder other than refractive disorders, breastfeeding women, pregnant female < 18 years of age -

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems